loading
Anika Therapeutics Inc stock is traded at $11.37, with a volume of 36,347. It is up +3.82% in the last 24 hours and up +4.58% over the past month. Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
See More
Previous Close:
$11.00
Open:
$11.11
24h Volume:
36,347
Relative Volume:
0.44
Market Cap:
$163.78M
Revenue:
$166.88M
Net Income/Loss:
$-74.18M
P/E Ratio:
-2.2426
EPS:
-5.07
Net Cash Flow:
$1.14M
1W Performance:
+2.06%
1M Performance:
+4.58%
6M Performance:
-30.24%
1Y Performance:
-59.26%
1-Day Range:
Value
$11.01
$11.53
1-Week Range:
Value
$10.49
$11.56
52-Week Range:
Value
$10.47
$28.60

Anika Therapeutics Inc Stock (ANIK) Company Profile

Name
Name
Anika Therapeutics Inc
Name
Phone
(781) 457-9000
Name
Address
32 WIGGINS AVENUE, BEDFORD, MA
Name
Employee
288
Name
Twitter
Name
Next Earnings Date
2025-03-12
Name
Latest SEC Filings
Name
ANIK's Discussions on Twitter

Compare ANIK with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
ANIK
Anika Therapeutics Inc
11.42 157.76M 166.88M -74.18M 1.14M -5.07
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
152.69 68.05B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.77 46.58B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.75 43.71B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.51 18.40B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
305.26 13.23B 2.99B 1.21B 1.13B 25.06

Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-17-25 Initiated B. Riley Securities Buy
Nov-01-24 Reiterated Barrington Research Outperform
Aug-14-23 Upgrade Barrington Research Mkt Perform → Outperform
Mar-07-23 Downgrade Barrington Research Outperform → Mkt Perform
Nov-09-22 Upgrade Barrington Research Mkt Perform → Outperform
Oct-14-22 Resumed Stephens Equal-Weight
Mar-09-22 Downgrade Barrington Research Outperform → Mkt Perform
Mar-09-22 Downgrade Stephens Overweight → Equal-Weight
Nov-16-21 Initiated Stephens Overweight
Jul-16-21 Initiated UBS Neutral
Dec-16-20 Upgrade Barrington Research Mkt Perform → Outperform
May-08-20 Downgrade Barrington Research Outperform → Mkt Perform
Jan-21-20 Upgrade Sidoti Neutral → Buy
Jan-10-20 Upgrade First Analysis Sec Outperform → Strong Buy
Nov-05-19 Initiated BWS Financial Sell
Sep-24-19 Reiterated Barrington Research Outperform
Sep-23-19 Downgrade First Analysis Sec Strong Buy → Outperform
Jul-25-19 Upgrade First Analysis Sec Neutral → Strong Buy
Feb-22-19 Downgrade First Analysis Sec Outperform → Neutral
Feb-22-19 Downgrade Sidoti Buy → Neutral
Jul-27-18 Upgrade Barrington Research Mkt Perform → Outperform
Jun-20-18 Downgrade Barrington Research Outperform → Mkt Perform
Jun-20-18 Downgrade First Analysis Sec Overweight → Equal-Weight
May-04-18 Upgrade Barrington Research Mkt Perform → Outperform
Feb-23-18 Downgrade Barrington Research Outperform → Mkt Perform
Jan-24-18 Upgrade First Analysis Sec Equal-Weight → Overweight
Oct-27-17 Reiterated Barrington Research Outperform
May-09-16 Upgrade Singular Research BUY - Long-Term → Buy
Apr-27-16 Downgrade Northland Capital Outperform → Market Perform
Feb-26-16 Reiterated Barrington Research Outperform
View All

Anika Therapeutics Inc Stock (ANIK) Latest News

pulisher
07:48 AM

What drives Anika Therapeutics Inc. stock priceSkyrocketing returns - Autocar Professional

07:48 AM
pulisher
Jul 22, 2025

Is Anika Therapeutics Inc. a good long term investmentExponential return rates - Autocar Professional

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Anika Therapeutics Inc. stockRapid wealth multiplication - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Anika Therapeutics Inc. Stock Analysis and ForecastTriple returns potential - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Why Anika Therapeutics Inc. stock attracts strong analyst attentionHigh Potential Stock Ideas - Newser

Jul 22, 2025
pulisher
Jul 18, 2025

Will Anika Therapeutics Inc. stock benefit from AI tech trendsROI Driven Alerts - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

Why Anika Therapeutics Inc. stock is on top investor watchlistsLow Risk Profit Ideas - Newser

Jul 18, 2025
pulisher
Jul 17, 2025

Published on: 2025-07-17 22:25:16 - Newser

Jul 17, 2025
pulisher
Jul 17, 2025

how anika therapeutics inc. stock performs during market volatilityLow Risk Scalping Alerts - Newser

Jul 17, 2025
pulisher
Jul 16, 2025

Anika Therapeutics: Orthopedic Growth and Pipeline Progress Amid Headwinds - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Anika to Issue Second Quarter 2025 Financial Results on Wednesday, July 30, 2025 - GlobeNewswire

Jul 16, 2025
pulisher
Jul 16, 2025

Orthopedics Leader Anika Announces Q2 2025 Earnings Call: Key Financial Results Coming July 30 - Stock Titan

Jul 16, 2025
pulisher
Jul 16, 2025

How Anika Therapeutics Inc. stock performs during market volatilityFree Stock Portfolio Optimization - Newser

Jul 16, 2025
pulisher
Jul 16, 2025

What makes Anika Therapeutics Inc. stock price move sharplyDaily Gain Forecast - Newser

Jul 16, 2025
pulisher
Jul 10, 2025

Anika Therapeutics Inc. (NASDAQ:ANIK) Shares Sold by Allspring Global Investments Holdings LLC - Defense World

Jul 10, 2025
pulisher
Jul 09, 2025

Breakthrough Growth Ahead: Adhesion Barrier Market Set to Surge - openPR.com

Jul 09, 2025
pulisher
Jul 04, 2025

Europe Viscosupplementation Market Growth in Future Scope - openPR.com

Jul 04, 2025
pulisher
Jul 03, 2025

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jul 03, 2025
pulisher
Jul 03, 2025

(ANIK) Technical Data - news.stocktradersdaily.com

Jul 03, 2025
pulisher
Jun 30, 2025

Anika Therapeutics, Inc.(NasdaqGS: ANIK) dropped from Russell Microcap Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 30, 2025

Anika Therapeutics, Inc.(NasdaqGS:ANIK) dropped from Russell 2000 Growth-Defensive Index - MarketScreener

Jun 30, 2025
pulisher
Jun 29, 2025

Anika Therapeutics, Inc.(NasdaqGS:ANIK) dropped from Russell Small Cap Comp Growth Index - MarketScreener

Jun 29, 2025
pulisher
Jun 28, 2025

ANIK SEC FilingsAnika Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Jun 28, 2025
pulisher
Jun 24, 2025

Anika Therapeutics Approves Key Proposals at Annual Meeting - TipRanks

Jun 24, 2025
pulisher
Jun 24, 2025

Anika Therapeutics stockholders approve incentive plan amendment and elect directors - Investing.com

Jun 24, 2025
pulisher
Jun 15, 2025

Comparing Vivos (OTCMKTS:RDGL) & Anika Therapeutics (NASDAQ:ANIK) - Defense World

Jun 15, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Cuts Stock Holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World

Jun 13, 2025
pulisher
Jun 10, 2025

Bank of America Corp DE Boosts Stake in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World

Jun 10, 2025

Anika Therapeutics Inc Stock (ANIK) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Anika Therapeutics Inc Stock (ANIK) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Nunes Anne
SVP, Chief Operations Officer
Mar 17 '25
Option Exercise
0.00
3,637
0
21,722
Colleran David
EVP, General Counsel, Corp Sec
Mar 17 '25
Option Exercise
0.00
6,448
0
49,847
Blanchard Cheryl R
President, CEO, Director
Mar 17 '25
Option Exercise
0.00
25,132
0
209,472
Nunes Anne
SVP, Chief Operations Officer
Mar 11 '25
Option Exercise
0.00
2,561
0
18,837
Colleran David
EVP, General Counsel, Corp Sec
Mar 11 '25
Option Exercise
0.00
7,663
0
45,649
Blanchard Cheryl R
President, CEO, Director
Mar 11 '25
Option Exercise
0.00
30,060
0
197,015
Nunes Anne
SVP, Chief Operations Officer
Mar 10 '25
Option Exercise
0.00
3,296
0
17,235
Colleran David
EVP, General Counsel, Corp Sec
Mar 10 '25
Option Exercise
0.00
5,465
0
39,590
Blanchard Cheryl R
President, CEO, Director
Mar 10 '25
Option Exercise
0.00
20,002
0
172,826
Nunes Anne
SVP, Chief Operations Officer
Oct 01 '24
Option Exercise
0.00
2,491
0
14,211
$73.25
price up icon 1.18%
$15.01
price up icon 0.54%
$9.375
price up icon 1.46%
drug_manufacturers_specialty_generic RDY
$14.63
price up icon 1.56%
$133.34
price up icon 0.43%
$304.89
price up icon 2.39%
Cap:     |  Volume (24h):